BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8630511)

  • 1. Von Hippel-Lindau tumor suppressor protein and transcription elongation: new insights into regulation of gene expression.
    Bertherat J
    Eur J Endocrinol; 1996 Feb; 134(2):157, 159. PubMed ID: 8630511
    [No Abstract]   [Full Text] [Related]  

  • 2. The molecular basis of von Hippel-Lindau disease.
    Iliopoulos O; Kaelin WG
    Mol Med; 1997 May; 3(5):289-93. PubMed ID: 9205944
    [No Abstract]   [Full Text] [Related]  

  • 3. The von Hippel-Lindau tumour suppressor protein: new perspectives.
    Ohh M; Kaelin WG
    Mol Med Today; 1999 Jun; 5(6):257-63. PubMed ID: 10366821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C.
    Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG
    Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.
    Feldman DE; Thulasiraman V; Ferreyra RG; Frydman J
    Mol Cell; 1999 Dec; 4(6):1051-61. PubMed ID: 10635329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of transcription elongation by the VHL tumor suppressor protein.
    Duan DR; Pause A; Burgess WH; Aso T; Chen DY; Garrett KP; Conaway RC; Conaway JW; Linehan WM; Klausner RD
    Science; 1995 Sep; 269(5229):1402-6. PubMed ID: 7660122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Hippel-Lindau disease: how does one gene cause multiple tumors?
    Roach ES
    Neurology; 1999 Jul; 53(1):7-8. PubMed ID: 10408528
    [No Abstract]   [Full Text] [Related]  

  • 8. The von Hippel-Lindau tumor suppressor protein.
    Ivan M; Kaelin WG
    Curr Opin Genet Dev; 2001 Feb; 11(1):27-34. PubMed ID: 11163147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Von Hippel-Lindau (VHL) gene analysis in Italian families with VHL disease.
    Montera M; Bellone E; Ajmar F; Mandich P
    Contrib Nephrol; 1997; 122():109-11. PubMed ID: 9399050
    [No Abstract]   [Full Text] [Related]  

  • 10. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.
    Barry RE; Krek W
    Trends Mol Med; 2004 Sep; 10(9):466-72. PubMed ID: 15350900
    [No Abstract]   [Full Text] [Related]  

  • 11. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.
    Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD
    Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [File no. 41. VHL (von Hippel-Lindau). Tumor suppressor gene].
    Soussi T
    Bull Cancer; 2000 Nov; 87(11):771-2. PubMed ID: 11190567
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor suppression and transcription elongation: the dire consequences of changing partners.
    Krumm A; Groudine M
    Science; 1995 Sep; 269(5229):1400-1. PubMed ID: 7660121
    [No Abstract]   [Full Text] [Related]  

  • 14. Interaction of von Hippel-Lindau tumor suppressor gene product with elongin.
    Pause A; Aso T; Linehan WM; Conaway JW; Conaway RC; Klausner RD
    Methods Enzymol; 1996; 274():436-41. PubMed ID: 8902823
    [No Abstract]   [Full Text] [Related]  

  • 15. VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease.
    Vortmeyer AO; Choo D; Pack S; Oldfield E; Zhuang Z
    Neurology; 2000 Aug; 55(3):460. PubMed ID: 10932304
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
    Wiesener MS; Eckardt KU
    Nephrol Dial Transplant; 2002 Mar; 17(3):356-9. PubMed ID: 11865075
    [No Abstract]   [Full Text] [Related]  

  • 18. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis.
    Richards FM; Schofield PN; Fleming S; Maher ER
    Hum Mol Genet; 1996 May; 5(5):639-44. PubMed ID: 8733131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Hippel-Lindau syndrome: hereditary cancer arising from inherited mutations of the VHL tumor suppressor gene.
    Humphrey JS; Klausner RD; Linehan WM
    Cancer Treat Res; 1996; 88():13-39. PubMed ID: 9239471
    [No Abstract]   [Full Text] [Related]  

  • 20. The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis.
    Decker HJ; Weidt EJ; Brieger J
    Cancer Genet Cytogenet; 1997 Jan; 93(1):74-83. PubMed ID: 9062583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.